Featured Publications
Decreased Overall Survival in HIV-associated Non–small-cell Lung Cancer
Hysell K, Yusuf R, Barakat L, Virata M, Gan G, Deng Y, Perez-Irizarry J, Vega T, Goldberg SB, Emu B. Decreased Overall Survival in HIV-associated Non–small-cell Lung Cancer. Clinical Lung Cancer 2020, 22: e498-e505. PMID: 33468393, PMCID: PMC8169710, DOI: 10.1016/j.cllc.2020.11.006.Peer-Reviewed Original ResearchConceptsCell lung cancerGeneral patientsNSCLC populationLung cancerCox proportional hazards modelYale-New Haven HospitalGeneral NSCLC populationOutcomes of patientsOverall median survivalRetrospective cohort studyPredictors of survivalKaplan-Meier curvesHIV-1 RNACopies/mLLog-rank testProportional hazards modelNew Haven HospitalCancer treatment regimensMedian CD4Antiretroviral therapyCohort studyMedian survivalOverall survivalHIV infectionMedian age
2019
Exosomal MicroRNAs Associate With Neuropsychological Performance in Individuals With HIV Infection on Antiretroviral Therapy.
OʼMeara T, Kong Y, Chiarella J, Price RW, Chaudhury R, Liu X, Spudich S, Robertson K, Emu B, Lu L. Exosomal MicroRNAs Associate With Neuropsychological Performance in Individuals With HIV Infection on Antiretroviral Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2019, 82: 514-522. PMID: 31714431, PMCID: PMC6857839, DOI: 10.1097/qai.0000000000002187.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyNeuropsychological performanceAntiretroviral therapyViral suppressionHIV infectionNeurocognitive dysfunctionExo-miRNAsEarly infection groupCentral nervous systemSystemic viral suppressionTyrosine receptor kinaseInfection groupChronic infectionPLWHCross-sectional examinationNervous systemEarly infectionNeuropsychological scoresInfectionConsistent findingNeuropsychological batteryHIVNeurodegeneration pathwaysDysfunctionTherapyAssessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer—A Phase 1 Study
Uldrick TS, Gonçalves PH, Abdul-Hay M, Claeys AJ, Emu B, Ernstoff MS, Fling SP, Fong L, Kaiser JC, Lacroix AM, Lee SY, Lundgren LM, Lurain K, Parsons CH, Peeramsetti S, Ramaswami R, Sharon E, Sznol M, Wang C, Yarchoan R, Cheever MA. Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer—A Phase 1 Study. JAMA Oncology 2019, 5: 1332-1339. PMID: 31154457, PMCID: PMC6547135, DOI: 10.1001/jamaoncol.2019.2244.Peer-Reviewed Original ResearchNon-Hodgkin lymphomaSafety of pembrolizumabB-cell lymphoproliferationCells/μLAntiretroviral therapyTumor responseKaposi's sarcomaStable diseaseCD4 countAdverse eventsAdvanced cancerMost treatment-emergent adverse eventsAdverse Events grade 2Anti-PD-1 therapyNCI Common Terminology CriteriaTreatment-emergent adverse eventsActive immunosuppressive therapyCommon Terminology CriteriaGood tumor responseT-cell countsAlanine aminotransferase levelsHIV viral loadPhase 1 studyImmune-related eventsCopies/mLPhase I study of pembrolizumab in people with HIV and cancer.
Uldrick T, Goncalves P, Abdul Hay M, Claeys A, Emu B, Ernstoff M, Fong L, Kaiser J, Kohrt H, Lacroix A, Lee S, Lundgren L, Lurain K, Parsons C, Peeramsetti S, Ramaswami R, Sharon E, Wang C, Yarchoan R, Cheever M. Phase I study of pembrolizumab in people with HIV and cancer. Journal Of Clinical Oncology 2019, 37: 2500-2500. DOI: 10.1200/jco.2019.37.15_suppl.2500.Peer-Reviewed Original ResearchAdverse eventsNon-Hodgkin lymphomaAntiretroviral therapyViral loadClinical benefitAnti-PD-1/PD-L1 therapyCD4 cells/μL.Elevated AST/ALTMedian age 57 yearsMulticenter phase 1 trialTreatment-emergent adverse eventsEmergent adverse eventsHBV/HCVSquamous cell skinPD-L1 therapyAge 57 yearsHIV viral loadAST/ALTPhase 1 trialCells/Cells/μL.Multicentric Castleman's diseaseAppropriate eligibility criteriaImmuno-oncology studiesNumber of cancers
2018
HIV and Age Do Not Synergistically Affect Age-Related T-Cell Markers
Farhadian S, Jalbert E, Deng Y, Goetz MB, Park LS, Justice A, Dubrow R, Emu B. HIV and Age Do Not Synergistically Affect Age-Related T-Cell Markers. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 77: 337-344. PMID: 29140874, PMCID: PMC5807137, DOI: 10.1097/qai.0000000000001595.Peer-Reviewed Original ResearchConceptsCD8 T cellsT-cell markersCD4 T cellsHIV infectionT cellsAntiretroviral therapyEffector memory CD4 T cellsImmune systemVeterans Aging Cohort StudyMemory CD4 T cellsNaive CD4 T cellsAging Cohort StudyT cell subsetsT-cell phenotypeCopies/mLCross-sectional studyRace/ethnicityChronic HIVUninfected subjectsUninfected menCohort studyHIV diseaseHigher proportionHIV serostatusHIV status
2014
Composition and Function of T Cell Subpopulations Are Slow to Change Despite Effective Antiretroviral Treatment of HIV Disease
Emu B, Moretto WJ, Hoh R, Krone M, Martin JN, Nixon DF, Deeks SG, McCune JM. Composition and Function of T Cell Subpopulations Are Slow to Change Despite Effective Antiretroviral Treatment of HIV Disease. PLOS ONE 2014, 9: e85613. PMID: 24465619, PMCID: PMC3897457, DOI: 10.1371/journal.pone.0085613.Peer-Reviewed Original ResearchConceptsT cell subpopulationsT cellsCell subpopulationsViral loadCMV-specific T-cell responsesNaïve T cell numbersLong-term viral suppressionIncrease of CD4Effective antiretroviral treatmentT cell frequenciesUndetectable viral loadT cell numbersT-cell depletionT cell responsesT-cell phenotypeNormal immune systemT cell populationsLow Ki67 expressionT cell functionIndependent homeostatic regulationDifferent proliferative responsesAntiretroviral therapyViral suppressionHIV diseaseAntiretroviral treatment
2008
HLA Class I-Restricted T-Cell Responses May Contribute to the Control of Human Immunodeficiency Virus Infection, but Such Responses Are Not Always Necessary for Long-Term Virus Control
Emu B, Sinclair E, Hatano H, Ferre A, Shacklett B, Martin JN, McCune JM, Deeks SG. HLA Class I-Restricted T-Cell Responses May Contribute to the Control of Human Immunodeficiency Virus Infection, but Such Responses Are Not Always Necessary for Long-Term Virus Control. Journal Of Virology 2008, 82: 5398-5407. PMID: 18353945, PMCID: PMC2395228, DOI: 10.1128/jvi.02176-07.Peer-Reviewed Original ResearchConceptsT cell responsesHLA class IElite controllersT cellsViremic controllersVirus controlClass IInterleukin-2HIV-specific T-cell responsesT cell-mediated controlUndetectable HIV RNA levelsHuman immunodeficiency virus (HIV) infectionHLA class I allelesProtective class IHIV RNA levelsHLA class I polymorphismImmunodeficiency virus infectionLong-term virus controlCell-mediated controlHuman immunodeficiency virusClass I allelesClass I polymorphismAntiretroviral therapyHIV controllersHIV transmissionRelationship between T Cell Activation and CD4+ T Cell Count in HIV-Seropositive Individuals with Undetectable Plasma HIV RNA Levels in the Absence of Therapy
Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, Shafer K, Hsue P, Emu B, Krone M, Lampiris H, Douek D, Martin JN, Deeks SG. Relationship between T Cell Activation and CD4+ T Cell Count in HIV-Seropositive Individuals with Undetectable Plasma HIV RNA Levels in the Absence of Therapy. The Journal Of Infectious Diseases 2008, 197: 126-133. PMID: 18171295, PMCID: PMC3466592, DOI: 10.1086/524143.Peer-Reviewed Original ResearchConceptsUndetectable plasma HIV RNA levelsT cell activationPlasma HIV RNA levelsHIV RNA levelsHIV-negative subjectsHigh LPS levelsCell activationCell countAntiretroviral therapyLPS levelsHigh T-cell activation levelsHIV-specific immune responsesT cell activation levelsUntreated human immunodeficiency virusPlasma lipopolysaccharide levelsRNA levelsHIV-seropositive individualsT-cell countsT cell lossHuman immunodeficiency virusAbsence of therapyActivation levelsCells/Measurable viremiaMucosal translocation
2005
Phenotypic, Functional, and Kinetic Parameters Associated with Apparent T-Cell Control of Human Immunodeficiency Virus Replication in Individuals with and without Antiretroviral Treatment
Emu B, Sinclair E, Favre D, Moretto WJ, Hsue P, Hoh R, Martin JN, Nixon DF, McCune JM, Deeks SG. Phenotypic, Functional, and Kinetic Parameters Associated with Apparent T-Cell Control of Human Immunodeficiency Virus Replication in Individuals with and without Antiretroviral Treatment. Journal Of Virology 2005, 79: 14169-14178. PMID: 16254352, PMCID: PMC1280210, DOI: 10.1128/jvi.79.22.14169-14178.2005.Peer-Reviewed Original ResearchConceptsHIV-specific T cellsT cellsT cell activationHIV diseaseImmune activationHuman immunodeficiency virus (HIV) replicationAdvanced HIV diseaseDrug-resistant viremiaGeneralized immune activationHIV-specific ILMultidrug-resistant HIVQuiescent immune systemActive antiretroviral therapyCytokine flow cytometryT cell controlHigh-level viremiaLow-level viremiaPresence of HIVT cell subsetsHuman immunodeficiency virusImmunodeficiency virus replicationT cell subpopulationsAbsence of therapyPresence of therapyAntiretroviral therapy